RE: Clinical validation not started......?2 Sep 2020 08:57
"Why would they tech transfer "immediately" if BBI hadn't produced a batch yet and these test will require no further validation? The BBI process has started. ISO13485 accreditation likely already achieved. Everything ready to go apart from CONDOR approval. Hopefully they pull their finger out!"
From the RNS, ICYMI:
"Avacta aims to begin clinical validation of the test as soon as possible using the first pilot batches."
"The Affimer reagents that we have generated are very specific to SARS-CoV-2 antigen and we are confident of meeting and exceeding the clinical performance requirements for identifying the most infectious people."
"I look forward to updating the market on progress in that regard, and will keep the market informed on the key next steps of clinical validation and regulatory approval."
This is clear. There is not yet a clinically validated product, never mind regulatory approval. What they're doing is, sensibly, ensuring that they have sufficient compliant manufacturing capacity to call down, as and when a clinically validated and regulatory approved product is ready to manufacture.